Showing results (421-430 of 105,852) with videos related to
Sort By:
Pageof 10,586
Pharmacotherapy|July 12, 2005
Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenemJoseph L Kuti, Sheryl Horowitz, Charles H Nightingale, et al.Annals of Tropical Paediatrics|December 1, 1987
Bacteriological quality of raw human milk: effect of storage in a refrigeratorS A Olowe, I Ahmed, S F Lawal, et al.Journal of Clinical Pharmacology|September 22, 2006
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patientsChonghua Li, Joseph L Kuti, Charles H Nightingale, et al.Antimicrobial Agents and Chemotherapy|November 13, 2013
In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposureAmira A Bhalodi, Mao Hagihara, David P Nicolau, et al.The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|October 2, 2008
Comparison of ceftriaxone versus triple drug regimen in the prevention of cesarean section infectious morbiditiesL O Alekwe, O Kuti, E O Orji, et al.Pharmacotherapy|November 26, 2008
Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infectionsSomvadee Laohavaleeson, Steven L Barriere, David P Nicolau, et al.International Journal of Molecular Sciences|July 29, 2023
Recruitment of Corticotropin-Releasing Hormone (CRH) Neurons in Categorically Distinct Stress Reactions in the Mouse BrainKrisztina Horváth, Balázs Juhász, Dániel Kuti, et al.Antimicrobial Agents and Chemotherapy|October 27, 2023
In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosisVictor H Ruiz, Andrew Fratoni, David P Nicolau, et al.Journal of Pharmacy Practice|November 11, 2017
Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal FunctionAbrar K Thabit, Mordechai Grupper, David P Nicolau, et al.Journal of Managed Care & Specialty Pharmacy|February 28, 2018
Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular DiseaseSandhya Mehta, Sabyasachi Ghosh, Stephen Sander, et al.Pageof 10,586